TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00087074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT02423382

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Silicone oil removal
Description: The patients in each group will receive the same procedure of silicone oil removal.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Silicone oil removal
Description: The patients in each group will receive the same procedure of silicone oil removal.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Silicone oil removal
Description: The patients in each group will receive the same procedure of silicone oil removal.
Study: NCT01617291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induced therapeutic hypothermia
Description: induced therapeutic hypothermia
Study: NCT00271336

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pentoxifylline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Study: NCT01469429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemoprevention
Description: Receive LBR lozenge PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemoprevention
Description: Receive LBR Saliva Substitute PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Receive Saliva Substitute placebo PO
Study: NCT02159456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous enteral feeding via infusion pump

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent enteral feeding via gravity-based infusion
Study: NCT01982266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GRADION™ Hip Total Cartilage Replacement (TCR)™
Study: NCT03857945

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative mobility device(s) training
Description: Patients in Group 1 (the intervention, that is the mobility device training group group) will receive training on the mobility device(s) with the physical therapy visit during their standard pre-operative care.
Study: NCT04445194

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant new coronavirus vaccine (CHO cell) low-dose group
Description: Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
Study: NCT02158039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: EUS-guided lavage of a pancreatic cystic neoplasm with ethanol solution. Ethanol was diluted to 80% using normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The final solution contained 1% lidocaine except in subjects allergic to local anesthetics.
Study: NCT04445194

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant new coronavirus vaccine (CHO cells) high-dose group
Description: Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant new coronavirus vaccine (CHO cells) placebo group
Description: Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
Study: NCT00987155

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ergometry
Description: MetamaxII Cortex ergospirometry system (Cortex Biophysik GmbH, Germany). Arm cycling ergometer (Ergomed 840L, Siemens, GermanyMonark, Sweden), Electrically braked wheelchair ergometer (VP 100, Handisoft France)
Study: NCT01777282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albiglutide
Description: Albiglutide is a fixed-dose, fully disposable pen injector system for delivery of albiglutide from a prefilled dual chamber glass cartridge that is an integral part of the pen. It is intended for single use by the subject. It is designed for manual reconstitution of the dose, priming, and insertion of the pen needle, and manual injection by the subject. The subject will inject albiglutide 30 mg weekly for 52 weeks (with optional uptitration to 50 mg weekly) subcutaneously into the abdomen, alternating between left and right sides. The pen is designed to work with standard pen needles.
Study: NCT00853450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6482
Description: Single intravenous infusion during a maximum of 5 hours
Study: NCT01573741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: a single infusion of ketamine hydrochloride (0.5 mg/kg) infused over 40 minutes
Study: NCT00841165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: Full face CPAP at 5cm H2O and 100% oxygen
Study: NCT00853450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Oral doses given once daily during 7 days. 300 mg on day 1 and 75 mg on day 2 to 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA
Description: 75 mg orally once daily during 7 days in each treatment arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: 75 mg orally once daily during 7 days in each treatment arm
Study: NCT03971643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilobelimab
Description: IV infusions of vilobelimab diluted in sodium chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilobelimab
Description: IV infusions of vilobelimab diluted in sodium chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilobelimab
Description: IV infusions of vilobelimab diluted in sodium chloride.
Study: NCT03333746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT00841165

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-rebreather oxygen mask
Description: Oxygen administered through a non-rebreather mask
Study: NCT02331771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Donepezil 5 mg once daily 2 days before ECT and continuing through the last ECT procedure.
Study: NCT01777282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albiglutide
Description: Albiglutide is a fixed-dose, fully disposable pen injector system for delivery of albiglutide from a prefilled dual chamber glass cartridge that is an integral part of the pen. It is intended for single use by the subject. It is designed for manual reconstitution of the dose, priming, and insertion of the pen needle, and manual injection by the subject. The subject will inject albiglutide 30 mg weekly for 52 weeks (with optional uptitration to 50 mg weekly) subcutaneously into the abdomen, alternating between left and right sides. The pen is designed to work with standard pen needles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albiglutide
Description: Albiglutide is a fixed-dose, fully disposable pen injector system for delivery of albiglutide from a prefilled dual chamber glass cartridge that is an integral part of the pen. It is intended for single use by the subject. It is designed for manual reconstitution of the dose, priming, and insertion of the pen needle, and manual injection by the subject. The subject will inject albiglutide 30 mg weekly for 52 weeks (with optional uptitration to 50 mg weekly) subcutaneously into the abdomen, alternating between left and right sides. The pen is designed to work with standard pen needles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albiglutide
Description: Albiglutide is a fixed-dose, fully disposable pen injector system for delivery of albiglutide from a prefilled dual chamber glass cartridge that is an integral part of the pen. It is intended for single use by the subject. It is designed for manual reconstitution of the dose, priming, and insertion of the pen needle, and manual injection by the subject. The subject will inject albiglutide 30 mg weekly for 52 weeks (with optional uptitration to 50 mg weekly) subcutaneously into the abdomen, alternating between left and right sides. The pen is designed to work with standard pen needles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonylurea
Description: Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biguanide
Description: Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glinide
Description: Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiazolidinedione
Description: Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-glucosidase inhibitor
Description: Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
Study: NCT01550237

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy daily verification reduced safety margins
Description: curative radiotherapy to 78 Gy in 39 fractions with daily CT position verification and reduced safety margins (7mm)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy weekly verification standard safety margins
Description: curative radiotherapy to 78 Gy in 39 fractions with weekly orthogonal position verification and standard safety margins (10-15 mm)
Study: NCT02847260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remodulin
Description: Treatment will be initiated whilst hospitalized at approximately 2.0 ng/kg/min with dose increments of 1- 2 ng/kg/min approximately every 12 hours according to clinical response and tolerability. Following subject discharge, the dose rate is increased by 1-2 ng/kg/min with dose increments separated by at least 24 hours. When a dose rate of 20 ng/kg/min is achieved dose increments can be increased at a rate of up to 4 ng/kg/min with dose increments separated by at least 24 hours depending on tolerability. The aim is to achieve a dose rate of at least 10, 20 and 30 ng/kg/min by the end of weeks 1, 4 and 12, respectively and a dose rate by the end of week 16 that achieves pre-defined treatment goals subject to clinical response and tolerability.
Study: NCT02331771

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule once daily 2 days before ECT and continuing through the last ECT procedure.
Study: NCT03333746

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT01219816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: Combination of chemotherapy + Epratuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: Vincristine + Dexamethasone + Epratuzumab
Study: NCT00443729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: raltegravir
Description: raltegravir 400 milligram (mg) by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo
Description: lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: lopinavir (+) ritonavir
Description: lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: placebo
Description: raltegravir 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
Study: NCT00017810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: The dietary intervention focused on diarrhea management using skill-building techniques that provided subjects with knowledge and a sense of confidence about making food choices.~Behavioral dietary intervention (Condition 1: treatment) - a low-fat, lactose-free, low insoluble fiber, high soluble fiber, and caffeine-free diet based on normal foods

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Self-Care
Description: Standard information regarding self-care and healthy living with HIV - focused on healthy living with HIV and did not include dietary restrictions or dietary information that could affect bowel movements.
Study: NCT03230578

Intervention type: OTHER
Intervention: Pharmacists & women's perspectives on pharmacist prescribed hormonal contraception
Description: The goal of this study is to identify the thoughts and perceptions of pharmacy access to hormonal contraception among rural women and pharmacists. This will be key in order to address concerns or perceived barriers in order to inform the implementation of this program.

Intervention type: OTHER
Intervention: Pharmacists & women's perspectives on pharmacist prescribed hormonal contraception
Description: The goal of this study is to identify the thoughts and perceptions of pharmacy access to hormonal contraception among rural women and pharmacists. This will be key in order to address concerns or perceived barriers in order to inform the implementation of this program.
Study: NCT03642262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucinex®
Description: Mucinex® 600 mg single dose ER bi-layer tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mucinex®
Description: Mucinex® 600 mg single dose ER bi-layer tablet
Study: NCT02420925

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Celiac Plexus Block
Description: Patients will undergo celiac plexus block via upper endoscopy with endoscopic ultrasound guidance. Injections will be performed using 0.75% bupivicaine and 40mg/ml of triamcinolone, ideally 1ml each directly into the celiac ganglia. If no ganglia is identifiable, then the injection will be performed into the celiac space, located at the take off of the celiac artery from the aorta.
Study: NCT04239755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline 100 MG Oral Tablet
Description: doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo in addition to the standard treatment.
Study: NCT03802526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1805-R1
Description: 1 tablet, multiple oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1805-R2
Description: 1 tablet, multiple oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1805-R1 and NVP-1805-R2
Description: NVP-1805-R1,1 tablet and NVP-1805-R2, 1 tablet, co-administration, multiple oral dosing
Study: NCT02298127

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Auricular acupressure
Description: For each auricular acupressure weekly session, magnetic ears tacks will be will be applied by certified traditional Chinese medicine practitioners according to the allocated group assignment, for a duration of one month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupressure
Description: For each auricular acupressure weekly session, magnetic ears tacks will be will be applied by certified traditional Chinese medicine practitioners according to the allocated group assignment, for a duration of one month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupressure
Description: For each auricular acupressure weekly session, magnetic ears tacks will be will be applied by certified traditional Chinese medicine practitioners according to the allocated group assignment, for a duration of one month.
Study: NCT03792945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local injection
Description: In addition to the local injection, carpal tunnel brace will be given.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: extracorporeal shock wave therapy
Description: In addition to all ESWT participants, carpal tunnel brace will be given.
Study: NCT01317771

Intervention type: PROCEDURE
Intervention: Open proximal biceps tendon tenodesis with an EndoButton
Description: Surgical fixation for bicipital pathology
Study: NCT03333746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02510157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: active comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: placebo controlled intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex
Description: sugammadex is administered in both groups to reverse deep neuromuscular blockade at the end of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugammadex
Description: sugammadex is administered in both groups to reverse deep neuromuscular blockade at the end of surgery
Study: NCT01929356

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Description: 20 minutes of chest physiotherapy by physiotherapist
Study: NCT04666441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN10933+REGN10987 combination therapy
Description: Administered IV or SC single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN10933+REGN10987 combination therapy
Description: Administered IV or SC single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN10933+REGN10987 combination therapy
Description: Administered IV or SC single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN10933+REGN10987 combination therapy
Description: Administered IV or SC single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN10933+REGN10987 combination therapy
Description: Administered IV or SC single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN10933+REGN10987 combination therapy
Description: Administered IV or SC single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered IV or SC single dose to match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered IV or SC single dose to match
Study: NCT03460340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prefrontal deep rTMS of H1 Coil
Description: prefrontal deep rTMS of H1 Coil

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: prefrontal deep rTMS of H1 Coil
Description: prefrontal deep rTMS of H1 Coil
Study: NCT01117116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate and salmeterol
Description: 45/4.5 two puffs twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate and salmeterol
Description: 45/4.5 two puffs twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide and formoterol
Description: 80/4.5 two puffs twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide and formoterol
Description: 80/4.5 two puffs twice daily
Study: NCT00461526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crofelemer
Description: 125 mg crofelemer vs. placebo
Study: NCT04205045

Intervention type: DIAGNOSTIC_TEST
Intervention: Lactose Breath Test
Description: Lactose Breath Test is performed during the recruitment step. Fasting subjects are asked to ingest 20 g of lactose in a 10% water solution. Breath samples are collected at baseline and every 30 min after lactose ingestion, for an overall test duration of 4 h. A cut-off value of 20 ppm over the baseline will be used to identify lactose malabsorbers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lactose Breath Test
Description: Lactose Breath Test is performed during the recruitment step. Fasting subjects are asked to ingest 20 g of lactose in a 10% water solution. Breath samples are collected at baseline and every 30 min after lactose ingestion, for an overall test duration of 4 h. A cut-off value of 20 ppm over the baseline will be used to identify lactose malabsorbers.

Intervention type: OTHER
Intervention: Gut permeability test
Description: A 3-sugar probes test is conducted by administering 5 g lactulose, 2 g mannitol and 2 g sucralose in water solution to fasting subjects. Urine are collected at baseline (before sugar ingestion) and for time periods 0-5 h and 5-24 h.

Intervention type: OTHER
Intervention: Gut permeability test
Description: A 3-sugar probes test is conducted by administering 5 g lactulose, 2 g mannitol and 2 g sucralose in water solution to fasting subjects. Urine are collected at baseline (before sugar ingestion) and for time periods 0-5 h and 5-24 h.

Intervention type: OTHER
Intervention: Milk Test
Description: Milk test will be performed by administering to fasting subjects a portion of 250 ml of semi-skimmed milk treated with ultra-high temperature (UHT). Glycaemia measurements, blood withdrawals and questionnaires completion will be performed at baseline and repeated after 30 minutes, 1, 2, 4 and 6 hours after milk ingestion. Urine collection will be performed at baseline and for 6 time intervals after milk ingestion (0-2, 2-4, 4-6, 6-8, 8-12, 12-24 hours).

Intervention type: OTHER
Intervention: Milk Test
Description: Milk test will be performed by administering to fasting subjects a portion of 250 ml of semi-skimmed milk treated with ultra-high temperature (UHT). Glycaemia measurements, blood withdrawals and questionnaires completion will be performed at baseline and repeated after 30 minutes, 1, 2, 4 and 6 hours after milk ingestion. Urine collection will be performed at baseline and for 6 time intervals after milk ingestion (0-2, 2-4, 4-6, 6-8, 8-12, 12-24 hours).
Study: NCT00079599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: A study drug, L-carnitine, titrating the doses from 0.5 g to 3 g to reduce the possibility of side effects, lasting for two weeeks followed by an extension phase where all patients recieved L-carnitine for an additional two weeks.
Study: NCT00461526

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: crofelemer
Description: 125 mg crofelemer vs. placebo
Study: NCT00079599

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo, where patients underwent the dose titration identical to the study patients, lasting for two weeeks followed by an extension phase where all patients recieved L-carnitine for an additional two weeks.
Study: NCT01732419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based training
Description: Home-based exercise training for cardiac patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Centre-based training
Description: Usual exercise training in an outpatient setting.